Key Points
- Neil Kumar, BridgeBio's CEO, sold 40,000 shares on April 9 at $74.62 for $2,984,800 under a pre-arranged Rule 10b5-1 plan, leaving him with 615,686 shares (a 6.10% reduction, valued at about $45.94M).
- The April sale continues a recent pattern of insider disposals—Kumar also sold 40,000 shares on March 12, 28,053 on Feb 19, and 40,000 on Feb 10, generating several million dollars in proceeds over the past months.
- Shares are trading near $77.87 (up ~4.4%), the company has a market cap of roughly $15.1B and a recent quarterly EPS miss despite strong revenue growth, while analysts maintain a consensus of " Moderate Buy" with an average target of $87.38.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $74.62, for a total value of $2,984,800.00. Following the completion of the transaction, the chief executive officer owned 615,686 shares of the company's stock, valued at $45,942,489.32. The trade was a 6.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neil Kumar also recently made the following trade(s):
- On Thursday, March 12th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.73, for a total transaction of $2,749,200.00.
- On Thursday, February 19th, Neil Kumar sold 28,053 shares of BridgeBio Pharma stock. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67.
- On Tuesday, February 10th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $71.94, for a total transaction of $2,877,600.00.
BridgeBio Pharma Stock Up 4.4%
NASDAQ BBIO opened at $77.87 on Tuesday. BridgeBio Pharma, Inc. has a 52 week low of $31.77 and a 52 week high of $84.94. The firm has a 50 day moving average of $70.91 and a two-hundred day moving average of $69.17. The stock has a market capitalization of $15.10 billion, a PE ratio of -20.60 and a beta of 1.09.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. The company's quarterly revenue was up 2521.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.40) EPS. On average, equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have issued reports on the company. Truist Financial lifted their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Morgan Stanley increased their price objective on BridgeBio Pharma from $96.00 to $98.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $89.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 10th. Weiss Ratings restated a "sell (d-)" rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Finally, TD Cowen reaffirmed a "buy" rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Twenty-four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average target price of $87.38.
Read Our Latest Report on BridgeBio Pharma
Institutional Trading of BridgeBio Pharma
A number of large investors have recently bought and sold shares of BBIO. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma in the first quarter valued at $35,000. First Trust Advisors LP grew its holdings in shares of BridgeBio Pharma by 200.4% during the second quarter. First Trust Advisors LP now owns 263,693 shares of the company's stock worth $11,386,000 after buying an additional 175,918 shares during the last quarter. Baird Financial Group Inc. grew its holdings in shares of BridgeBio Pharma by 1.8% during the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company's stock worth $1,816,000 after buying an additional 731 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in BridgeBio Pharma in the 2nd quarter valued at about $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in BridgeBio Pharma by 2.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company's stock valued at $4,132,000 after acquiring an additional 2,206 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
